Kevin Bitterman, an insider at Disc Medicine Inc (IRON), sold 389,422 shares of the company's stock on December 14, 2025, at a price of $91.18 per share. This transaction totaled $35.51 million. Following this sale, Bitterman retains 389,422 shares of Disc Medicine.
Disc Medicine, based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing treatments for hematologic diseases. The firm went public on August 12, 2020, and currently has a market cap of $3.5 billion. Its product pipeline includes bitopertin, aimed at treating erythropoietic porphyrias and Diamond-Blackfan Anemia, as well as DISC-0974 for anemia related to myelofibrosis and chronic kidney disease.
Insider sales can arise from various motivations, including diversification, tax planning, or personal financial needs. While significant selling activity may attract attention, such transactions do not inherently reflect a negative outlook on the company. Investors are encouraged to consider insider activities as part of a broader analysis, including patterns across multiple insiders and various timeframes.
This move underscores the importance of transparency in insider transactions, which must be reported to the SEC. Such data points can help investors gauge executive sentiment but should not be the sole factor in investment decisions.
Disc Medicine's upcoming earnings report is scheduled for August 5, 2026, with an estimated EPS of -$1.64 and expected revenue of $5.7 million.